Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
"eltanexor multiple myeloma" - Google News
Get the latest updates from "eltanexor multiple myeloma" - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated about 2 years ago
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - Stockhouse
about 2 years ago
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in...
Karyopharm Names New Head of Investor Relations | News | wfmz.com - 69News WFMZ-TV
about 2 years ago
Karyopharm Names New Head of Investor Relations | News | wfmz.com 69News...
Karyopharm Names New Head of Investor Relations - PR Newswire
about 2 years ago
Karyopharm Names New Head of Investor Relations PR NewswireAs longtime CMO exits...
Karyopharm Therapeutics : Corporate Presentation March 2022 - Marketscreener.com
about 2 years ago
Karyopharm Therapeutics : Corporate Presentation March 2022 Marketscreener.com
KARYOPHARM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com
about 2 years ago
KARYOPHARM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results...
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - BioSpace
about 2 years ago
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed...
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - Yahoo Finance
about 2 years ago
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed...
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - Yahoo Finance
about 2 years ago
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed...
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - Yahoo Finance
about 2 years ago
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed...
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - PR Newswire
about 2 years ago
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed...
Karyopharm Provides US Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer - PR Newswire
about 2 years ago
Karyopharm Provides US Regulatory Update on Selinexor in Advanced or Recurrent Endometrial...
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer - Benzinga
about 2 years ago
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial...